The domestic pharmaceutical industry has entered a new round of transformation and pain, and the adjustment of executives of multinational pharmaceutical companies has accelerated

Since the beginning of this year, the transfer of senior executives in the pharmaceutical industry has been relatively frequent, and a large number of directors, deputy general managers and supervisors of domestic and foreign pharmaceutical companies have changed one after another
.
It is worth noting that some of these companies have frequent personnel changes and have successively announced the appointment of a number of executives
.
Recently, Pfizer appointed Chu Nan as the head of the digestive system/urinary/hematological oncology field of the Oncology Business Unit, and reported directly to Wang Yiqin, the General Manager of the Oncology Business Unit.
The appointment took effect today (March 28, 2022)
.
It is reported that Chu Nan will be in charge of managing the sales and marketing teams of Pfizer China in the field of digestive system/urology/hematological oncology, formulate effective product and market strategies, develop and promote the business development of product pipelines with strategic thinking, and make better use of it.
product potential to drive rapid business growth
.
It is worth noting that, in fact, less than a month after Pfizer assumed the position of president of Pfizer China in September last year, the organizational structure of China has been adjusted.
Since then, Pfizer has successively announced a number of related personnel appointments
.
It is understood that Pfizer China currently has 6 independent business units: hospital emergency, oncology, rare diseases, inflammation and immunity, vaccines, and broad market
.
Among them, Zhang Jianhui was appointed as the general manager of the broad market division; Li Jinhui was appointed as the general manager of the hospital emergency division; Dai Wenjie was appointed as the general manager of the inflammation and immunity division; Zhang Lingyan was appointed as the general manager of the vaccine division
.
Today, the head of the digestive/urinary/hematological oncology therapeutic area is also in the dust
.
Some pharmaceutical companies have successively appointed a number of executives, and naturally there are also corporate executives who leave one after another
.
In recent years, due to changes in the pharmaceutical environment, both multinational and local pharmaceutical companies are actively adapting to the changes and making corresponding business and personnel adjustments
.
Among them, many pharmaceutical companies have successively left executives and technical talents to seek external development opportunities
.
For example, AstraZeneca issued an internal announcement not long ago, saying that Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reasons
.
At the same time, Yu Qiran, the current new product planning and marketing director, will also serve as the head of the project management office of the general manager of oncology.

.
According to incomplete statistics, 9 senior executives from AstraZeneca have left since last year, including Zhu Tong, vice president of AstraZeneca China, head of cardiovascular, renal and metabolic business units; AstraZeneca China and county market leaders He Shuzhen; General Manager of AstraZeneca China Oncology Business Unit Yin Min; AstraZeneca China Vice President and Head of County Business Unit Du Haochen,
etc.
The industry believes that the frequent news of personnel changes in pharmaceutical companies shows from the side that China's pharmaceutical industry is going through a new round of transformation and pain.
More and more frequently, at the same time, executive changes have become the norm
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.